Windlas Biotech Limited (WINDLAS) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.016x

Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has a cash flow conversion efficiency ratio of 0.016x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs66.60 Million ≈ $720.25K USD) by net assets (Rs4.16 Billion ≈ $45.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Windlas Biotech Limited stock valuation for the company's overall valuation and market capitalisation.

Windlas Biotech Limited - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Windlas Biotech Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Windlas Biotech Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Windlas Biotech Limited ranked by their cash flow conversion efficiency. Explore cash flow quality index of Windlas Biotech Limited to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Rithm Acquisition Corp. NYSE:RAC	-0.001x
QST International TWO:8349	0.030x
MEDI ASSIST HEALTHCARE SERVICES LIMITED NSE:MEDIASSIST	0.018x
H+H International A/S CO:HH	0.054x
Brompton Split Banc Corp TO:SBC	0.008x
Armada Acquisition Corp. II NASDAQ:XRPN	0.002x
Meeka Metals Ltd AU:MEK	0.120x
Leenos Corp KQ:039980	-0.007x

Annual Cash Flow Conversion Efficiency for Windlas Biotech Limited (2018–2025)

The table below shows the annual cash flow conversion efficiency of Windlas Biotech Limited from 2018 to 2025. View today's stock price for Windlas Biotech Limited for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	Rs5.06 Billion ≈ $54.70 Million	Rs681.87 Million ≈ $7.37 Million	0.135x	-44.33%
2024-03-31	Rs4.50 Billion ≈ $48.66 Million	Rs1.09 Billion ≈ $11.78 Million	0.242x	+59.79%
2023-03-31	Rs4.02 Billion ≈ $43.50 Million	Rs609.65 Million ≈ $6.59 Million	0.152x	+555.31%
2022-03-31	Rs3.95 Billion ≈ $42.69 Million	Rs91.30 Million ≈ $987.37K	0.023x	-59.80%
2021-03-31	Rs1.99 Billion ≈ $21.53 Million	Rs114.54 Million ≈ $1.24 Million	0.058x	-51.77%
2020-03-31	Rs2.10 Billion ≈ $22.67 Million	Rs250.06 Million ≈ $2.70 Million	0.119x	+23.77%
2019-03-31	Rs1.94 Billion ≈ $20.94 Million	Rs186.54 Million ≈ $2.02 Million	0.096x	-59.28%
2018-03-31	Rs1.25 Billion ≈ $13.52 Million	Rs295.91 Million ≈ $3.20 Million	0.237x	--

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic

Market Cap

$250.31 Million

Rs23.15 Billion INR

Market Cap Rank

#15731 Global

#794 in India

Share Price

Rs1098.15

Change (1 day)

-2.75%

52-Week Range

Rs718.35 - Rs1154.75

All Time High

Rs1154.75